

Journal of Clinical Immunology

A report of novel STIM1 deficiency and 6 year follow up of two previous cases associated with mild immunological phenotype

--Manuscript Draft--

Manuscript Number:	JOCI-D-18-00238R3
Full Title:	A report of novel STIM1 deficiency and 6 year follow up of two previous cases associated with mild immunological phenotype
Article Type:	Letter to Editor
Keywords:	STIM1; immunodeficiency; calcium flux
Corresponding Author:	Sinisa Savic, Ph.D, M.D University of Leeds Faculty of Medicine and Health Leeds, UNITED KINGDOM
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Leeds Faculty of Medicine and Health
Corresponding Author's Secondary Institution:	
First Author:	Laura Rice
First Author Secondary Information:	
Order of Authors:	Laura Rice Claire Stockdale Ian Berry Sean O'Riordan Karen Pysden Rashida Anwar Roger Rushambuza Moira Blyth Sonal Srikanth Yousang Gwack Yasser M. El-Sherbiny Clive Carter Sinisa Savic, Ph.D, M.D
Order of Authors Secondary Information:	
Funding Information:	
Suggested Reviewers:	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

A report of novel STIM1 deficiency and 6 year follow up of two previous cases associated with mild immunological phenotype

Laura Rice^{1*}, Claire Stockdale^{2*}, Ian Berry³, Sean O’Riordan⁴, Karen Pysden⁵, Rashida Anwar¹, Roger Rushambuza⁶, Moira Blyth³, Sonal Srikanth⁷, Yousang Gwack⁷, Yasser M. El-Sherbiny^{8,9,10} Clive Carter², Sinisa Savic^{2,10}

¹ Leeds Institute of Medical Research at St James's, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, UK

² Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, UK

³ Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK

⁴ Department of Paediatric Immunology, Leeds General Infirmary, Leeds, UK

⁵ Department of Paediatric Neurology, Leeds General Infirmary, Leeds, UK

⁶ Department of Radiology, Calderdale and Huddersfield NHS Foundation Trust, UK

⁷ Department of Physiology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA

⁸ Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK.

⁹ Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt.

¹⁰ National Institute for Health Research—Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, UK

* Equal contribution

Correspondence to: Dr Sinisa Savic, s.savic@leeds.ac.uk

To the Editor,

Loss of function or null mutations of Stromal interaction molecule 1 (STIM1) are known to cause early-onset combined immunodeficiency (CID) disease with recurrent and chronic infections, autoimmunity, haemolytic anaemia, ectodermal dysplasia, muscular weakness and myalgia (1). STIM1 and ORAI1 form the calcium release-activated calcium (CRAC) channels and are involved in calcium signalling, which is especially important in T cells for activation, proliferation and cytokine production (2). ORAI1 forms the pore in the plasma membrane and STIM1 is a calcium sensor protein that activates the ORAI1 when the endoplasmic reticulum (ER) Ca²⁺ stores are depleted.

STIM1-deficient patients have impaired T cells and NK cell function, but usually a normal distribution of the major immune cell types, including T cells, B cells and natural killer (NK) cells with the T cell repertoire that is normally comparable to healthy individuals (3). STIM1 deficiency results in no store-operated calcium entry (SOCE) in T cells and as a result the patient's cells cannot respond appropriately to T cell receptor (TCR) activation or pharmacological agents such as ionomycin, thapsigargin (TG), which typically trigger Ca²⁺ influx (1).

Recently a new biological role for STIM1 has been identified. STIM1 was found to act as a negative regulator for Stimulator of Interferon Genes (STING). STIM1 was shown to inhibit STING trafficking by physically interacting with STING and retaining it at the ER membrane. This interaction is important in maintaining STING in an inactive state (4). Several *STING* mutations which have previously shown to cause an autoinflammatory condition named STING-associated vasculopathy with onset in infancy (SAVI), appear to exert their dominant effects by weakening the interaction between STIM1 and STING (4).

Here we describe a 5-year-old boy of consanguineous Pakistani background with overlapping clinical features of CID and autoinflammatory disorder. The boy was initially referred to pediatric immunology services with a history of recurrent sinopulmonary infections. The patient was born at full term by normal vaginal delivery following a normal pregnancy. An inguinal hernia was noted when six days old and was repaired the same day. He initially fed well. At six months of age it was noted that he was quieter and delayed in his development. He sat at 18 months and walked at 3 years and crawls upstairs using his head as support. Currently, at 5 years he is alert and engaging but has speech delay putting 2-3 words together. He

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

can scribble and draw circles. He was fully toilet-trained at 3 years. He is in mainstream education but requires additional support.

When examined at 5 years, he weighed 11.5kg (-5SD), with a height of 94.2cm (-4SD) and head circumference of 46.1cm (-4SD). He is slim, with reduced proximal upper limb muscle bulk and globally in his lower limbs, lordosis and is hypermobile across all his joints. He has proximal weakness leading to a waddling gait, and uses a Gowers manoeuvre to stand. He has no facial weakness, no ophthalmoparesis but has fixed dilated pupils.

The patient infection history included recurrent sinopulmonary infections with one episode of pneumonia requiring hospital admission and intravenous antibiotics. He had received all his primary vaccinations, including MMR, without significant complications. He was hospitalized for a complicated primary varicella zoster infection due to bacterial suprainfection requiring antibiotic treatment. In addition, he had several hospitalizations with suspected infections, but despite having documented fevers, no apparent infective cause was found and on several occasions, he recovered without receiving antibiotics. A full dental clearance was performed due to recurrent tooth infections and tooth enamel deficiency. Other characteristics include, ichthyosis, anhidrosis and low zinc levels [7.8 $\mu\text{mol/l}$ (reference range 10.3-18.1)]. Although he was described to have severe eczema his skin eruptions mainly affected the palms, soles of the feet and cheeks, (cold exposed areas), and would start with blistering sterile pustular psoriasiform rash, eventually resulting in skin desquamation. Zinc replacement did not lead to improvement, and there was minimal benefit from application of topical steroid. The patient also had pronounced nail dystrophy (Figure 1). There was no history of Raynaud's phenomena.

He has two other siblings who are fit and healthy. The pedigree is shown in Figure 2A.

The initial investigations including full blood count, creatinine kinase, screen for inherited metabolic diseases and MRI scan of the head were all normal. The immunological work up showed essentially normal numbers of T, B and NK cells. More detailed phenotyping revealed, detectable regulatory T cells and unremarkable memory B cell profile. Immunoglobulin profile (IgG, IgA, IgM and IgG subclasses) was normal with marginally elevated total IgE. The levels of specific antibodies to

1 tetanus and Haemophilus influenzae type b (Hib) were adequate and showing a
2 good response to previous vaccination. Interestingly, the total anti-pneumococcal
3 antibody levels were reduced, however, following a challenge vaccination with
4 pneumovax, the levels increased well above the protective titre (from 6.2 to 120.7
5 $\mu\text{g/ml}$)
6
7

8
9 Considering some of the clinical features, diagnosis of STIM1 or ORAI1
10 deficiency was suspected. The parents consented for genetic testing. A modified
11 exome sequencing approach was performed using Agilent SureSelectXT with All
12 Exon v5 capture library and sequenced on Illumina HiSeq 3000 for 2x150-bp paired-
13 end sequencing. Genetic testing identified a homozygous deletion in *STIM1*
14 NM_003156.3:c.478del, p.(Ser160ValfsTer15), and a homozygous *CANT1* mutation
15 NM_001159772.1:c.676G>A, p.(Val226Met) (Figure 2A). This known pathogenic
16 *CANT1* mutation has previously been described in multiple patients with “Kim-
17 variant” Desbuquois dysplasia, usually in compound heterozygosity with another
18 mutation (5,6). These patients have normal clinical examination but advanced carpal
19 age, elongated phalanges and short metacarpals on radiological examination. Only
20 one patient, reported to have “Kim-variant” Desbuquois dysplasia, was homozygous
21 for the *CANT1* c.676G>A mutation but little phenotypic information was provided
22 (5,6). The same homozygous mutation has also been described in a single patient
23 with autosomal recessive multiple epiphyseal dysplasia (7). That patient did not
24 have many of the features of “Kim-variant” Desbuquois dysplasia but had developed
25 the degenerative arthrosis of the hands and spine by the age of 25 years.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 The novel single nucleotide deletion at c.478 in *STIM1* results in a frameshift
43 such that translation terminates prematurely within the sterile alpha motif (SAM), the
44 region regulating stability within STIM proteins. The truncated polypeptide of 173
45 amino acids (wild type *STIM1* polypeptide has several splice variants, one of which
46 is 791 amino acids, another form is 685) lacks important functional domains of
47 *STIM1*, including the transmembrane region and the CRAC activation domain (CAD).
48 We used western blot to investigate the expression of *STIM1* in the patient’s (P1)
49 PBMCs, and failed to detect either the full length or the truncated variant of *STIM1*.
50 However, we did detect expression of *STIM2*, a homologue of *STIM1*. The former
51 was not expressed in PBMCs from HC (Figure 1B).
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 The functional impact of these mutations was investigated further. Regarding
3 the *STIM1* variant we performed flow cytometry T receptor spectraphenotyping and
4 showed essentially normal TCR repertoire (Figure 1 Suppl). A single Vb region
5 (Vb7.2) was missing from patient's T cells, however the clinical significance of this is
6 unknown. Proliferative responses to Phytohaemagglutinin (PHA) were adequate
7 (although reduced at high concentrations) and the response to anti-CD3 was
8 preserved (Figure 2A Suppl). There was significantly reduced upregulation of CD25
9 following anti-CD3 *in-vitro* stimulation whilst upregulation of HLA-DR and CD69 was
10 normal (Figure 2B suppl). Measurement of store-operated Ca²⁺ entry in patient T
11 cells revealed a complete lack of calcium influx in response to anti-CD3/anti-CD28
12 stimulation and TG, as seen in Figure 2C.
13
14
15
16
17
18
19
20
21

22 A skeletal survey was performed to investigate the impact of the *CANT1*
23 variant on the patient's phenotype. His overall small stature was consistent with
24 previous reports regarding the effects of this *CANT1* variant. His skeletal survey
25 revealed the abnormal early maturation of carpal bones seen in *CANT1*-related
26 disorders. It also showed a gentle curve scoliosis of the cervicothoracic spine, which
27 is in keeping with *CANT1*-related disorders. The skeletal survey did not convincingly
28 demonstrate the so-called monkey-wrench deformity of the femoral necks, shortened
29 metacarpal bones, and other abnormalities which have previously been described in
30 patients with Desbuquois dysplasia (8,9) (Figure 3). Some of the radiological
31 features are progressive and may appear at a later date but the skeletal phenotype
32 is more in keeping with the patient described as having MED (7). That patient was
33 also homozygous for the *CANT1* c.676G>A and it has already been proven that this
34 mutation significantly reduces, but does not eliminate, the nucleotidase activity of
35 *CANT1*(5). In comparison, most patients described as having "Kim-variant"
36 Desbuquois dysplasia have this mutation alongside a second mutation anticipated to
37 cause a premature stop codon or shown to cause more significantly reduced *CANT1*
38 nucleotidase activity (5). As has already been hypothesised, it is likely that
39 homozygosity for the p.(Val226Met) mutation in *CANT1* causes a less severe
40 phenotype than the "Kim-variant" Desbuquois dysplasia (7), which occurs when a
41 more damaging mutation is present on the other allele.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 We have previously reported two other cases with a homozygous mutation in
59 *STIM1*, resulting in impaired store-operated calcium entry, reduced natural killer and
60
61
62
63
64
65

1 T cell function, but without overt clinical immunodeficiency (10) (Table 1). We
2 arranged a follow up visit to assess their clinical progress and repeat immunological
3 assessment following their initial investigations in 2012. From the immunological
4 perspective, 6 years later, both cousins were generally well and had not suffered
5 from any serious, frequent or opportunistic infections. They both continued to
6 experience some problems with anhidrosis and mild muscle weakness but were
7 otherwise unaffected by their condition. They did not report any new symptoms.
8 Repeat immunological assessment showed that V:3 (older cousin as designated in
9 the original publication) had persistent CD8 lymphopenia (8%, 86 cells/ μ l), new mild
10 B cell lymphopenia (88 cells/ μ l) (ref: 100-500 cells/ μ l), but also normal
11 immunoglobulin profile with adequate levels of specific antibodies to Hib, tetanus and
12 pneumococcus. Furthermore, repeated PHA and anti-CD3 T cell stimulation
13 indicated normal responses. TCR repertoire, assessed by T receptor
14 spectraphenotyping, showed no abnormalities. The results of the tests on the second
15 cousin (V:2) are shown in Table 1. These are essentially unchanged apart from the
16 anti-nuclear antibody test which on this occasion was negative.
17
18
19
20
21
22
23
24
25
26
27
28

29 We have previously shown that monocytes and peripheral blood mononuclear
30 cells (PBMCs) from the patient (P1) with the novel *STIM1* deletion mutation have
31 significantly increased interferon-stimulated gene (ISG) expression compared to
32 healthy controls (HC) (4). This was consistent with expected loss of STIM1-mediated
33 STING inhibition (4). We wanted to check if this STIM1 function is also affected in
34 patients harboring p.L74P *STIM1* variant. We obtained blood from the patient (V:2)
35 and PBMCs were separated by gradient separation using Lymphoprep (Stem Cell
36 Technologies) and monocytes were purified from PBMCs using a monocyte
37 separation kit II (# 130-091-153, Miltenyi Biotec). The ISG expression was measured
38 using TaqMan probes (for details please see supplements). While ISG expression in
39 PBMCs and monocytes from V:2 was reduced compared to what we previously have
40 shown for P1(4) there was significant increase in several ISG compared to HC,
41 suggesting that the p.L74P variant has effect on STIM1-mediated STING inhibition
42 (Figure 4). We have previously shown that overexpression of p.L74P variant in
43 HEK293 cells results in preferential localization of the mutated protein to puncta
44 rather than the ER (10). Using Western blot and two sets of anti-STIM 1 antibodies
45 (one specific for the N-terminal and the other for protein C-terminal, for details please
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 see supplements) we failed to detect any STIM1 expression in V:2 PBMCs. This
2 suggest that p.L74P mutation under physiological conditions affects the protein
3 stability, resulting in reduced expression, and therefore reduced inhibition of STING.
4

5 The new patient we describe in this report has two monogenic conditions,
6 STIM1 deficiency and CANT1-related disorder. However, most of the clinical
7 manifestations are due to STIM1 deficiency. The CANT1 variant will be responsible
8 for the short statue, mild scoliosis and advanced carpal age but other features such
9 as premature arthritis may develop with time. On the other hand, the nature of
10 genetic defect found in *STIM1* is more severe (deletion compared to amino acid
11 substitution in *CANT1*) and the non-immunological features typically associated with
12 STIM1 deficiency (anhidrosis, amelogenesis imperfecta and muscle weakness) are
13 fully expressed. Furthermore, biochemical studies of the new STIM1 variant, clearly
14 showed loss of expression of full length STIM1 (4).
15
16
17
18
19
20
21
22
23

24 STIM 1 deficiency is still quite rare, however with increasing number of cases
25 being reported world-wide a more complete picture of the clinical phenotypes
26 associated with this disorder is beginning to emerge. The homozygous mutations
27 resulting in amino acid substitution and total lack of protein expression have both
28 been described. Although there are too few cases to determine if there is genotype-
29 phenotype correlation in this condition (Table 2), the only fatalities associated with
30 STIM1 deficiency have only been reported with the mutations resulting in total loss of
31 the protein expression (LOE) (1,11,12), however, SCID-like phenotypes have been
32 described in patients where STIM1 mutations lead to loss of function without LOE
33 (12,15).
34
35
36
37
38
39
40
41

42 The non-immunological features of the case we report here overall fit with the
43 classical STIM1 deficiency due to enamel deficiency, anhidrosis and muscle
44 weakness; but the mild immunological phenotype, in a patient lacking full length
45 STIM1 expression is a novel presentation. Furthermore, this patient has several
46 clinical features suggestive of autoinflammatory complications. Although he does not
47 have pulmonary involvement (fibrosis) or severe ulceration and necrosis of the skin,
48 which are typical for SAVI, he did have pustular rash developing at the cold exposed
49 areas of the skin and acral surfaces, which have been reported in this condition (16).
50 He also had a history of unexplained fevers, however, to an extent, this could be
51 explained by anhidrosis. Interestingly, patient V:2, who also has increased ISG,
52 does not have any clinical features to suggest autoinflammatory condition.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Therefore, the effect of SAVI disinhibition in STIM1 deficiency on clinical phenotype is complex and difficult to predict. Nevertheless, overlap between PID and systemic autoinflammatory disorders is increasingly being recognized, and this case adds to this growing disease area.

There are scant long-term outcome data for patients with STIM1 deficiency. The patients we reported first in 2012 and reinvestigated now in 2018 have not seemingly developed any overt immunological problems and reassuringly the repeat investigations of their immune system do not show any significant deterioration. It is interesting that lack of calcium flux seen in the patients' T cells, either due to total lack of full length STIM 1 expression or due to truncated STIM1, has not resulted in a more profound immunodeficiency. We assume that a form of compensatory mechanism must be in place to account for this outcome. One possibility is that other related proteins such as STIM2, a homologue of STIM1, might provide this role. Indeed, when we examined expression of STIM2 in PBMCs from P1 and V:2, the expression of the protein was increased compared to HC, in fact HC PBMCs did not show any expression of STIM2 under resting conditions. In addition, high interferon drive was detected in both STIM1 deficient cases, and this might offer some protection against viral pathogens. Lastly, considering immunological and non-immunological features of STIM1 deficiency, this condition should be thought of as another form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), similarly to what has recently been proposed for ORA1 deficiency (17).

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Acknowledgements

This research is supported by grant from CSL Behring and by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Reference

1. Picard C, McCarl C-A, Papolos A, et al. *STIM1* Mutation Associated with a Syndrome of Immunodeficiency and Autoimmunity. *The New England journal of medicine*. 2009;360(19):1971-1980. doi:10.1056/NEJMoa0900082.
2. Feske S, Prakriya M, Rao A, Lewis RS. A severe defect in CRAC Ca²⁺ channel activation and altered K⁺ channel gating in T cells from immunodeficient patients. *The Journal of Experimental Medicine*. 2005;202(5):651-662. doi:10.1084/jem.20050687.
3. Feske S, Picard C, Fischer A. Immunodeficiency due to mutations in *ORAI1* and *STIM1*. *Clinical immunology (Orlando, Fla)*. 2010;135(2):169-182. doi:10.1016/j.clim.2010.01.011.
4. Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, Rice L, Seo GJ, Calmettes G, Ramakrishna C, Cantin E, An DS, Sun R, Wu T-T, Jung JU, Savic S, Gwack Y. *STIM1* regulates type I interferon response by retaining *STING* at the endoplasmic reticulum. *Nat Immun* 2018- accepted for publication
5. Furuichi T, Dai J, Cho T, et al, *CANT1* mutation is also responsible for Desbuquois dysplasia, type 2 and Kim variant, *Journal of Medical Genetics* 2011;48:32-37. doi:10.1136/jmg.2010.080226
6. Kim OH, Nishimura G, Song HR, Matsui Y, Sakazume S, Yamada M, Narumi Y, Alanay Y, Unger S, Cho TJ, Park SS, Ikegawa S, Meinecke P, Superti-Furga A. A variant of Desbuquois dysplasia characterized by advanced carpal bone age, short metacarpals, and elongated phalanges: report of seven cases. *Am J Med Genet A*. 2010;152A(4):875-85
7. Balasubramanian K, Li B, Krakow D, Nevarez L, Ho PJ, Ainsworth JA, Nickerson DA, Bamshad MJ, Immken L, Lachman RS, Cohn DH. MED resulting from recessively inherited mutations in the gene encoding calcium-activated nucleotidase *CANT1*. *Am J Med Genet A*. 2017;173(9):2415-2421. doi:10.1002/ajmg.a.38349
8. Nizon M, Huber C, De Leonardis F, Merrina R, Forlino A, et al Further Delineation of *CANT1* Phenotypic Spectrum and Demonstration of Its Role in Proteoglycan Synthesis. *Hum Mutat* 2012; 33(8): 1261–1266.
9. Bui C, Huber C, Tuysuz B, Alanay Y, 1 Mutations in Desbuquois Dysplasia Type 2. *Am J Hum Genet*. 2014 Mar 6; 94(3): 405–414.
10. Parry DA, Holmes TD, Gamper N, et al. A homozygous *STIM1* mutation impairs store-operated calcium entry and natural killer cell effector function without clinical immunodeficiency. *The Journal of Allergy and Clinical Immunology*. 2016;137(3):955-957.e8. doi:10.1016/j.jaci.2015.08.051.
11. Byun M, Abhyankar A, Lelarge V, et al. Whole-exome sequencing-based discovery of *STIM1* deficiency in a child with fatal classic Kaposi sarcoma. *The Journal of Experimental Medicine*. 2010;207(11):2307-2312. doi:10.1084/jem.20101597.
12. Fuchs S, Rensing-Ehl A, Speckmann C, et al. Antiviral and regulatory T cell immunity in a patient with *STIM1* deficiency. *Journal of Immunology (Baltimore, Md : 1950)*. 2012;188(3):1523-1533. doi:10.4049/jimmunol.1102507.
13. Schaballie H, Rodriguez R, Martin E, Moens L, Frans G, Lenoir C, Dutré J, Canioni D, Bossuyt X, Fischer A, Latour S, Meyts I, Picard C. A novel hypomorphic mutation in *STIM1* results in a late-onset immunodeficiency. *J Allergy Clin Immunol*. 2015;136(3):816-819.e4. doi: 10.1016/j.jaci.2015.03.009

14. Wang S, Choi M, Richardson AS, Reid BM, Seymen F, Yildirim M, et al. STIM1 and SLC24A4 are critical for enamel maturation. *J Dent Res* 2014;12:94S-100S.
15. Maus M, Jairaman A, Stathopoulos PB, Muik M, Fahrner M, Weidinger C, Benson M, Fuchs S, Ehl S, Romanin C, Ikura M, Prakriya M, Feske S. Proc Natl Acad Sci U S A. Missense mutation in immunodeficient patients shows the multifunctional roles of coiled-coil domain 3 (CC3) in STIM1 activation. 2015;112(19):6206-11
16. Canna SW, Goldbach-Mansky R. New monogenic autoinflammatory diseases--a clinical overview *Semin Immunopathol*. 2015;37(4):387-94
17. Lian J, Cuk M, Kahlfuss S, Kozhaya L, Vaeth M, Rieux-Laucat F, Picard C, Benson MJ, Jakovcevic A, Bilic K, Martinac I, Stathopoulos P, Kacs Kovics I, Vraetz T, Speckmann C, Ehl S, Issekutz T, Unutmaz D, Feske S. ORAI1 mutations abolishing store-operated Ca²⁺ entry cause anhidrotic ectodermal dysplasia with immunodeficiency. *J Allergy Clin Immunol*. 2018;142(4):1297-1310.e1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Figure 1. Skin desquamation on the palms and nail dystrophy. These pictures were taken following
4 initial blistering of the skin

5
6 Figure 2. Patient with STIM1 deficiency. A) Mutation segregation (N/A- not available, the genotypes of
7 two siblings are not available, but both are healthy and neither have any clinical features to suggest
8 *STIM1* or *CANT1* deficiency). B) Western blot showing expression of STIM1 and STIM2 in PBMC from
9 HC, P1 and V:2, representative blot from 2 separate experiments, *Non-specific binding C) Calcium
10 flux in Patient T cells compared to healthy control (HC). T cells were incubated for 1 hour at 37°C in
11 0% CO₂ with 2µM fura-2 AM in standard bath solution (SBS) with 0.01% pluronic acid (Invitrogen).
12 Cells were seeded at 5x10⁵ cells/well. T cells were stimulated for 90 seconds by either Thapsigargin
13 (TG) at 1µM or the TCR was activated by soluble CD3 at 1µg/ml (Clone OKT3). For TCR stimulation
14 the plate was coated with anti-CD28 (1µg/ml, Clone CD28.2). Fura-2 was excited at 340 nm and 380
15 nm and emission was collected at 510 nm. Measurements were taken on a 96-well fluorescence
16 plate reader (FlexStation III, Molecular Devices)

17
18
19
20 Figure 3. The image on the left (A) is a DP x-ray of the hand of a normal 5 year old boy. The
21 ossification centre of the ulnar epiphysis (ue) is not visible and the scaphoid (S) and trapezium and
22 trapezoid (T) ossifications centres are very small. The study was performed following penetrating
23 trauma and the density between the middle and ring metacarpal bones is a glass foreign body.
24 Compare with the appearances of our patient's hand on the right (B) where the ulnar epiphysis
25 ossification centre is clearly visible and the radial sided carpal bones are nearly fully formed with
26 appearances more typical of an 8 or 9 year old boy. C) Xray of thoracolumbar Spine". It demonstrates
27 a gentle scoliosis of the cervicothoracic spine.

28
29 Figure 4. Interferon-stimulated gene (ISG) expression in patients' and healthy controls (HC)
30 monocytes. V:2, patients with homozygous pL74P *STIM1* mutation. Statistical analysis was carried
31 out using two-tailed/unpaired Student's t-test *p < 0.05 **p < 0.005 and ***p < 0.0005

32
33
34 Figure 1. Suppl. TCR repertoire as assessed by T receptor spectraphenotyping. The arrow is showing
35 a missing Vb7.2 expression on patients' T cells.

36
37 Figure 2. Suppl. A) Phytohaemagglutinin (PHA, 3 differed concentrations 5,10 and 100 µg/ml) and
38 anti-CD3 T cell proliferation (P1 red 2 separate experiments) Healthy controls (HC black) X3 B) CD69,
39 HLA-DR and CD25 expression on T cells from the patient (P1 red) and 3 HC black following
40 stimulation with anti-CD3 for 48 hours

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1 Immunological findings

	Present study (P1)	Schaballie et al 2015*	Vaeth et al 2017	Parry et al 2015	Present study (V:2 V:3)**	Summary of all data***	
Lymphocyte count	1/1↔	8/8↔	1/1↔	2/2↔	2/2↔	12/12↔	
CD3+	1/1↔	8/8↔		2/2↔	2/2↔	11/11↔	
CD4+	1/1↔	8/8↔		2/2↔	2/2↔	11/11↔	
CD8+		CD27+ CD45RA+ (naïve)	1/1↔	3/4↓		2/2↔	3/7↓
		CD27+ CD45RA- (memory)	1/1↔	2/2↑		2/2↔	2/5↑
		CD27-CD45RA- (memory effector)	1/1↑	2/2↑		2/2↔	3/5↑
		CD25+CD127- (Treg)		2/4↓		2/2↔	2/6↓
			1/1↔	2/8↓	1/2↓	1/2↓	3/11↓
		CD27+ CD45RA+ (naïve)	1/1↔	2/3↓		1/2↓	2/6↓
		CD27+ CD45RA- (memory)	1/1↑	1/2↑		1/2↓	2/5↑
		CD27- CD45RA- (memory effector)	1/1↔	1/2↑		2/2↔	1/5↑
		CD27- CD45RA+ (effector)	1/1↓	2/3↑		1/2↑	3/6↑
CD19+			1/1↔	1/8↓	1/1↔	1/2↑	10/12↔
		CD27+ IgM+ IgD+	1/1↔	2/2↓		1/2↓	2/5↓
		CD27+ IgM- IgD-	1/1↔	1/2↓		1/2↓	1/5↓
		CD27- IgM+ IgD+	1/1↔	1/2↑		1/2↑	1/5↑
CD56+ CD16+ (NK cells)	1/1↔	8/8↔	1/1↔	2/2↔	2/2↔	12/12↔	
Tcell Vbeta repertoire	1/1↔	1/2↔			2/2↔	2/5↔	
T lymphocyte proliferation test							
		PHA	1/1↔	5/5↓	1/1↓	2/2↔	6/9↓
		Anti CD3	1/1↔	5/5↓		2/2↔	5/8↓
		Tetanus toxoid		1/1↓			1/1↓
		VZV		1/1↓			1/1↓
IgG	1/1↔	3/8↑ (2/8↓)			2/2↔	2/2↔	3/11↑
IgA	1/1↔	2/8↑ (2/8↓)			2/2↔	1/2↑	3/11↑
IgM	1/1↔	2/8↓			0/2↓	2/2↔	2/11↓
IgE	1/1↑	3/4↔			1/2↓	1/2↓	1/7↓
Pneumococcal antibody response	1/1↔	1/2↓			2/2↔	2/2↔	1/4↓

*Includes patients from Picard et al 2009, Byun et al 2010 and Fuchs et al 2012; **V:2 and V:3 originally reported by Parry et al in 2015, follow up investigation on the same patients reported in this study (2018)*** No immunological findings were available for Wang et al 2014, therefore total number of patients is 12; ↔ Normal; ↓ low; ↑ high;

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2 Clinical features of STIM1 deficiency

Study	Picard et al 2009			Byun et al 2010	Fuchs et al 2012		wang et al 2014	Schaballie et al 2015		Parry et al 2015		Vaeth et al 2017	Present study	Summary
Patient ID from the study	V-1	V-4	V-7	P4	P5	P6	iV:1	P 7	P 8	V2	V3	P1	P1	
STIM1 mutation	E136X*	Not known	E136X*	1,538-1G>A*	Arg429Cys*	Arg429Cys*	p.Arg426Cys*	p.165P>Q*	p.165P>Q*	p.L74P*	p.L74P*	p.L374P*	p.Ser160fs*	
Predicated protein effect	LOE	N/A	LOE	LOE	LOF	LOF	LOF	LOE/LOF	LOE/LOF	LOE/LOF	LOE/LOF	LOF	LOE/LOF	
Age at last examination**	9	1.5	6	2	6	1.7	6	21	8	11	21	22	4	
Immunodeficiency	1	1	1	1	1	1	0	1	1	0	0	1	1	10/13
Immune dysregulation	AIHA, ITP, LN, H/S	AIHA, ITP, LN, H/S	ITP	AIHA, LN H/S	AIHA ITP	AIHA ITP	0	LN, H/S	0	0	Transient ITP	0	0	8/13
Muscular hypotonia/weaknes	1	1	1	0	1	1	0	1	1	0	0	1	1	9/13
Mydriasis	1	1	1	0	1	1	0	0	0	0	0	NR	1	6/12
Anhydrosis	NR	NR	NR	0	1	1	0	1	0	1	1	1	1	6/10
Enamel hypoplasia/defect	1	0	0	0	1	1	0	1	1	1	1	1	1	9/13
Died	1	1	0	1	0	1	0	0	0	0	0	0	0	4/13
Alive	0	0	1	0	1	0	1	1	1	1	1	1	1	9/13
Skin involvement	0	0	0	Eczematous lesions fingers and feet	Generalised eczema	Severe eczema	0	Psoriasis	Chronic dermatitis	Mild eczema	0	0	Atypical eczema ichthyosis,	7/13
GI involvement	0	0	0	0	Colitis	0	0	Colitis	0	0	0	0	0	2/13
Nail involvement	0	0	0	0	Nail dysplasia	0	1	0	Brittle nails	0	0	0	Nail dystrophy	3/13

* homozygous; ** age given in years: LOF-Loss of function; LOE-loss of expression; 1=yes; 0 no; AIHA-autoimmune hemolytic anemia; ITP-autoimmune thrombocytopenia; LN-lymphadenopathy; H/S- hepatosplenomegaly; NR-not reported

Figure 1



Figure 2




Figure 3




Figure 4

